Michael Berens, among the study’s writers. Dr. Berens is Director from the Malignancy and Cell Biology Department and head from the Glioma Research Laboratory at TGen. ‘Understanding the mutations that are traveling a tumor as time passes may help us forecast the genetic span of the disease, in order that we are able to intervene in a far more specific style,’ stated the research’ senior article author Dr. C. Ryan Miller, a known person in UNC Lineberger and affiliate teacher in the UNC College of Medication. Preliminary treatment of glioblastoma includes surgical removal from the tumor, radiation and chemotherapy using the drug temozolomide .